ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors

Luigi Fattore, Debora Malpicci, Emanuele Marra, Rosalba Camerlingo, Giuseppe Roscilli, Francesca Belleudi, Antoni Ribas, Rita Mancini, Maria Rosaria Torrisi, Luigi Aurisicchio, Paolo Antonio Ascierto, Gennaro Ciliberto

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalJournal of Translational Medicine
DOIs
Publication statusAccepted/In press - Jan 15 2015

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Fattore, L., Malpicci, D., Marra, E., Camerlingo, R., Roscilli, G., Belleudi, F., Ribas, A., Mancini, R., Torrisi, M. R., Aurisicchio, L., Ascierto, P. A., & Ciliberto, G. (Accepted/In press). ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors. Journal of Translational Medicine, 1-2. https://doi.org/10.1186/1479-5876-13-S1-K3